Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress  by Takamiya, Rina et al.
FEBS Open Bio 2 (2012) 328–333
journa l homepage: www.e lsev ier .com/ locate / febsopenbioResolvinE1maintainsmacrophage functionunder cigarette smoke-inducedoxidative
stressRina Takamiyaa,b,d,*, Koichi Fukunagab, Makoto Aritae, Jun Miyatab, Hiroyuki Sekic, Naoto Minematsub,
Makoto Suematsua, Koichiro Asanob,f
aDepartment of Biochemistry, School of Medicine, Keio University, Japan
bDivision of Pulmonary Medicine, Department of Medicine, School of Medicine, Keio University, Japan
cDepartment of Anesthesiology, School of Medicine, Keio University, Japan
dSystems Glycobiology Research Group, Advanced Science Institute, RIKEN, Japan
eDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan
fDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Japan
a r t i c l e i n f o
Article history:
Received 19 July 2012
Received in revised form 10 September 2012






a b s t r a c t
Cigarette smoke (CS) induces oxidative stress, which disables macrophage function. In this study, we
examined whether Resolvin E1 (RvE1), a pro-resolving mediator known to enhance macrophage func-
tions, attenuates the damage ofmacrophages by CS extract (CSE) induced oxidative stress. RvE1 blocked
p47phox translocation to plasma membrane induced by CSE in a macrophage cell line, RAW264.7 cells,
resulting in suppression of superoxide production. Furthermore, pretreatment of RAW264.7 cells with
RvE1 restored the phagocytic activity and reduced cell death induced by treatment of CSE. These results
suggest that RvE1 plays important roles in preservingmacrophage function under CS-induced oxidative
stress.
c© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
Chronic obstructive pulmonary disease (COPD), comprised of
small airway diseases and pulmonary emphysema, is currently the
fourth leading cause of death globally, with mortality rates continu-
ing to increase [1]. Cigarette smoke (CS), a complex mixture of over
4700 components including reactive oxygen species (ROS), is a major
risk factor for the development of COPD [1–4], and an imbalance be-
tween oxidants and anti-oxidants plays an essential role in its patho-
genesis [5]. In smokers, ROS generation is also enhanced in alveolar
macrophages, a condition that is related to tissue injury and cell death
in COPD [6].
On the other hand, alveolarmacrophages play a key role in thehost
defense to lung infectionswhich is detrimental to the prognosis of pa-
tients with COPD [7]. We, as well as other investigators, have shown
that, when macrophages are exposed to CSE, their ability to phago-
cytose apoptotic cells [8–10], microorganism [11], and polystyrene
beads [12] is decreased, compared to several type of macrophagesAbbreviations: CS, cigarette smoke; CSE, cigarette smoke extract; COPD, chronic ob-
structive pulmonary disease; NOX2, NADPH oxidase2; RvE1, Resolvin E1; ROS, reactive
oxygen species
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http://dx.doi.org/10.1016/j.fob.2012.10.001that were not exposed, and served as a cell culture model. It has also
been demonstrated that a relationship exists between the phago-
cytic activity of macrophages, the resolution of acute inﬂammation
[13]; decreased clearance of apoptotic neutrophils (efferocytosis) in
macrophages from CS extract (CSE)-exposed mice, as we previously
demonstrated [8]. Collectively, this results in the sustained inﬂam-
mation of and further destruction of the lungs. Hence, a drug that can
restore the protective functions of macrophages might be useful for
the treatment of COPD.
It has been demonstrated that an increased intake of omega-3
polyunsaturated fatty acids is associated with a decreased risk of
COPD and emphysema [14] and with an improvement in symptoms
and exercise capacity [15,16]. Resolvin E1 (RvE1) is one of the bioac-
tive lipid mediators synthesized from omega-3 polyunsaturated fatty
acids, which not only suppresses acute inﬂammation by decreasing
neutrophil inﬁltration, but also actively promotes the resolution of
inﬂammation by enhancing the clearance of apoptotic neutrophils by
macrophages [17–21]. In addition, RvE1has been shown to block TNF-
α- or FMLP-induced superoxide generation in human neutrophils
[22]. Furthermore, we recently showed that RvE1 attenuates lung
inﬂammationwithout compromising host defense in amurinemodel
of aspiration pneumonia [23].
The objective of this studywas to determinewhether RvE1 attenu-
ates CSE-induced oxidative stress and cell death in a macrophage cell
line, RAW264.7, and at the same time, increases phagocytic functions
against E. coli.. Open access under CC BY-NC-ND license.
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Materials and methods
Preparation of CSE
Research grade 3R4F cigarettes (Kentucky Tobacco Research Insti-
tute) were used to prepare the CSE. CSE was prepared fresh for each
experiment by bubbling the smoke from one cigarette through 10 ml
of medium in a 15 ml conical tube followed by passing through a
0.22 μ m ﬁlter to remove large particles and maintain sterility. This
solution was designated as 100% CSE [8].
Cell culture and CSE exposure in vitro
A murine macrophage cell line, RAW264.7 cells (5 × 104 cells/
well DMEM containing 10% FBS), were grown in 6-well plates for 24 h
followed by serum-starvation for 2 h prior to the stimulation by CSE.
RAW264.7 cells were incubated with or without RvE1 (1–100 nM,
Cayman Chemical) for 30 min, and then CSE (1% or 10%) or acrolein
(10 or 100 μM, Tokyo Chemical Industry, Japan) was added into the
indicated wells.
Measurement and visualization of ROS generation
Intracellular ROS generation was detected with 2′,7′-
dichloroﬂuorescein diacetate (DCFH-DA) (Molecular Probes), a
membrane-permeable precursor that yields ﬂuorogenic duchloroﬂu-
orescin (DCF) through oxidation [24]. In a typical run, the cells were
incubated with 10 μM DCFH-DA for 30 min at 37 ◦C in DMEM, and
washed twice with PBS, and then analyzed using a FACScan ﬂow
cytometer (Beckton Dickinson).
Measurement of p47-phox translocation.
RAW264.7 cells were pelleted and resuspended in fractionation
buffer (10 mM HEPES, pH 7.4, 0.25 M sucrose, 5 mM EGTA, 2.5 mM
MgCl2) and sonicated. Unbroken cells and nuclei were pelleted by
centrifugation (13,000 × g, 10 min, 4 ◦C), and the supernatants were
separated intomembrane and cytosol fractions by ultracentrifugation
(100,000 × g, 60 min, 4 ◦C) [25]. The membranes were solubilized
in cell lysis buffer (Cell Signaling Technology) containing protease
inhibitor (Roche).
Western blot analysis
Cells were lysed in cell lysis buffer (Cell Signaling Technology)
with complete protease inhibitors (Roche). Protein extracts were
subjected to SDS–PAGE (Bio-Rad), transferred to PVDF membranes
(Bio-Rad), and then probed with an anti-Akt antibody (1:1000; Cell
Signaling Technology), an anti-HO-1 antibody (1:1000; Stressgen
Biotechnologies), an anti-p47-phox antibody (1:1000; Millipore), or
an anti-actin antibody (1:1000; Sigma–Aldrich). After incubationwith
a peroxidase-conjugated secondary antibody, the immunoreactive
bands were visualized using an enhanced chemiluminescence kit (GE
Health Care).
Phagocytic function assay
The phagocytic function of RAW264.7 cells was assessed using a
Vybrant phagocytosis kit (Molecular Probes) with the followingmod-
iﬁcations. RAW264.7 cells (5 × 104 cells/well)were grown in 96-well
microplates for 12 h prior to stimulation. After incubation with RvE1
for 30 min, the cells were treated with CSE or acrolein for 2 h, after
which, 20 μl of ﬂuorescein-labeled E. coli bioparticles (5 mg/ml) was
added. Two hours later, the ﬂuorescence intensity of each well was
determinedwith a ﬂuorescence plate reader (Wallac ARVO SX), using
480 and 520 nm for excitation and emission, respectively. Phagocyticindex (PI) is presented as the relative ﬂuorescence intensity in the
experimental samples compared to the intensity in the non-treated
cells.
Confocal laser scanning microscopy
RAW264.7 cells were grown on glass-bottom dishes and ﬁxed by
treatment with 4% paraformaldehyde for 10 min on ice. Cells were
incubated with 100 ng/ml of tetramethyl rhodamine isothiocyanate
(TRITC)-labeled phalloidin (Sigma–Aldrich) and then analyzed using
confocal lasermicroscopy (Leica). To identify the size of the cells, they
were measured under a microscope, and the image was processed
digitally using an eight-bit image analyzer (NIH Image software).
Cell death analysis
To determine the extent of damage to cells by CSE in the presence
or absence of RvE1 (10 nM), RAW264.7 cells were stainedwith a 0.4%
trypan blue solution at room temperature for 3min and the cellswere
then counted in a hemocytometer. The cells were then stained cells
observed under a microscope. For statistical analysis, four different
digital images of cells under the microscope (each covering 50–100
cells to be counted) were acquired and the stained cells were counted
[26].
Assessment of cell viability
Cell viability was assessed by MTT cell proliferation (Cayman
Chemical) following the manufacturer’s instructions.
Statistical analysis
For a comparison between more than two groups, and multiple
comparisons, an ANOVA test, which followed by the Bonferroni/Dunn
multiple comparison test, was used. The datawere analyzed using the
Graphpad Prism4 (GraphPad Software). Statistical signiﬁcance was
accepted at P value of less than 0.05. The number of samples per
group ( n) is speciﬁed in the ﬁgure legends.
Results
RvE1 blocks CSE induced ROS production
We measured intracellular ROS levels in RAW264.7 cells using
a DCFH-DA probe, and the results indicated that ROS levels were
elevated after a 4 h exposure to 10% CSE (Fig. 1(A)). RvE1 at a con-
centration of 10 nM reduced the elevation in intracellular ROS level
induced by CSE in RAW 264.7 cells (Fig. 1(A)). In order to determine
whether RvE1 suppressed ROSproduction by inhibiting the activation
ofNADPHoxidase 2 (NOX2),we checked the translocation of p47phox
from the cytosol to the cell membrane by Western blot analysis. CSE
exposure (10%, 4 h) induced a shift in p47phox immunoreactivity to
the plasmamembrane in RAW264.7 cells, as previously reported [27],
and this translocationwasblockedby treatmentwith10nMRvE1 (Fig.
1(B)). Exposure to CSE (10%, 4 h) induced the expression heme oxyge-
nase (HO)-1, a sensitive marker for oxidative stress [28], the levels of
which were also reduced in the cells that had been treated with CSE
and RvE1 (Fig. 1(C)). These results suggest that RvE1 may suppress
the CSE-induced p47phox translocation to the plasmamembrane, re-
sulting in the inhibition of NOX2 and a reduction in ROS production
in RAW264.7 cells.
RvE1 attenuates CSE-induced damage of phagocytic function
The exposure of RAW264.7 cells to 1% or 10% CSE for 4 h resulted
in a decrease in phagocytic activities in a dose-dependent manner
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Fig. 1. RvE1 inhibited the intracellular ROS production induced by CSE in RAW264.7
cells. After incubation with 10 nM RvE1 for 30 min, RAW264.7 cells were exposed
to CSE (10%) for 4–6 h. (A) Relative ROS concentrations in cells were quantiﬁed by
ﬂow cytometric analysis of DCF ﬂuorescence. Data show data from three representa-
tive experiments. (B) Localization of p47phox in the cytosolic and membrane fractions
examined by immunoblot analysis. Data are representative of three experiments. (C)
Induction of HO-1 expression examined by Western blot analysis. Data are represen-
tative of two experiments.
without evidence of impairing cell viability (Fig. 2(A) and Fig. S1)
[8]. The repressed phagocytic function in these cells was reversed
by the pretreatment with RvE1 at concentrations of 1–100 nM (Fig.
2(B)). We then examined the effects of RvE1 (10 nM) on the acrolein-
induced phagocytic defects. Acrolein is a low molecular weight, α,β-
unsaturated aldehyde that is present in high concentrations (> 4.0
parts per million) in cigarette smoke [29,30]. As shown in Fig. 2(C),
acrolein also suppressed phagocytic function, whichwas ameliorated
by the pretreatment with RvE1.
RvE1 represses CSE induced cytoskeletal changes
A recent study indicated that the polymerization of actin at the
leading edge had greatly deteriorated after CSE treatment, resulting
in an impaired phagocytic function inmacrophages [8]. Therefore, the
attenuation of CSE impaired-phagocytic function by RvE1 prompted
Fig. 2. RvE1 restored the phagocytic activity decreased by treatment of CSE or acrolein
in RAW264.7 cells. RAW264.7 cells treated with CSE, acrolein, and/or RvE1 were in-
cubated with FITC-labeled E. coli. Phagocytic index (PI) is presented as the relative
ﬂuorescence intensity in the experimental samples compared to the intensity in the
non-treated cells, arbitrarily designated as 1.0. (A) Dose-response effects of CSE or
acrolein (4 h) on phagocytic activity. *P < 0.05 vs. control (n = 5). Pretreatment with
RvE1 enhanced phagocytic activity in the presence of CSE (B) or acrolein (C). *P < 0.05
vs. control. †P < 0.05 vs. CSE or acrolein alone (n = 4).
us to examine whether RvE1 was capable of restoring CSE induced-
actin modiﬁcation. Polymerized actin ﬁbers were stained with phal-
loidin and analyzed by laser scanning confocal microscopy. As shown
in Fig. 3(A), 4 h-CSE exposure evoked a retraction in the leading-
edge that occurred simultaneously with the reduction of cell size. The
mean size of the CSE-exposed RAW264.7 cells was 66 ± 17% that
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Fig. 3. RvE1protected thedisruptionof cytoskeletal structure causedbyCSEor acrolein
in RAW264.7 cells. RAW264.7 cells were incubated with RvE1 or vehicle for 30 min,
CSE (10%, A) or acrolein (10 μM, B) was then added, followed by incubation for 4 h.
Representative ﬂorescent images with TRITC-labeled phalloidin are shown. Cell size
was measured under a microscope after collecting 30 cells from each culture. Open
bar: vehicle-treated cells. Dark gray bar: CSE- or acrolein-treated cells. Light gray bar:
acrolein-treated cells in the presence of RvE1 (10nM). The line in each column indicates
the mean value. *P < 0.05 vs. control. †P < 0.05 vs. CSE or acrolein alone (n = 4). Scale
bar: 25 μM.
of the control cells. When we treated RAW 264.7 cells with 10 nM
RvE1 30min prior to CSE-exposure, CSE-induced cytoskeletal disrup-
tion was recovered to 87 ± 21% that of the control cells. Stabilizing
actions of RvE1 were also observed when the stimulus was replaced
with acrolein (Fig. 3(B)).
RvE1 suppresses CSE-induced cell death and degradation of the Akt
protein
Although short-term (4 h) exposure to CSE had little effect on cell
viability, a longer exposure (24 h) to 10% CSE in serum free medium
resulted in a reduced cell viability and an increased the ratio of dead
cells, compared with vehicle treated cells (Fig. 4(A) and (B)). Under
this condition, pretreatment with 10 nM RvE1 before CSE exposure
Fig. 4. RvE1 rescuedCSE-inducedcell deathby inRAW264.7 cells. RAW264.7 cellswere
incubated for 24 h in serum-free DMEMmedium including 10% CSE in the presence or
absence of 10 nM RvE1. (A) Viability of cells was determined by MTT assays. *P < 0.05
vs. control. †P < 0.05 vs. CSE alone (n = 3). (B) Dead cells were determined by means
of a trypan blue exclusion test. *P < 0.05 vs. control. †P < 0.05 vs. CSE alone (n = 4). (C)
Expression of the Akt proteinwas determined byWestern blot analysis. Representative
data from two experiments.
increased cell viability and reduced the cell death (Fig. 4(A) and (B)).
Acrolein also induced the reduction of cell viability, which was ame-
liorated by the pretreatment with RvE1 (Fig. S2). It has been reported
that a long-term exposure to CSE induces the proteasomal degrada-
tion of Akt, and that this leads to the death of human lung ﬁbroblasts
[31]. We, therefore, examined whether RvE1 could affect Akt degra-
dation caused byCSE. As shown in Fig. 4(C), the levels of total Aktwere
decreased after RAW264.7 cells were subjected to a 24 h-CSE expo-
sure, whereas pretreatment with 10 nM RvE1 blocked CSE-induced
Akt protein degradation.
Discussion
Highly ROS present in CS are thought to contribute to the develop-
ment of COPD. Furthermore, they simulate macrophages to produce
more ROS mainly through the activation of NOX [27]. The ﬁndings
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reported herein indicated that RvE1 blocks the elevation in intra-
cellular peroxide levels, p47phox translocation, and the induction of
HO-1 induced by CSE (Fig. 1). These data suggest that RvE1modulates
CS-induced superoxide generation by suppressing NOX2 activation.
Although ROS have been classically believed to be necessary for the
killing of pathogens, recent studies have been shown that the dele-
tion of NOX2 improves the resolution of lung viral infections [32,33].
Therefore, the paradoxical role of RvE1 to NOX2 may be important
for the resolution of CS-induced inﬂammation by suppressing the
excessive production of ROS in the lung.
Investigators have previously shown that alveolar macrophages
from COPD patients exhibit a reduced phagocytic activity to E. coli
[8,9]. Our data also demonstrate that E. coli clearance bymacrophages
was impaired by a 4 h-exposure to CSE or acrolein. As we previ-
ously reported [8], the CSE-induced suppression of phagocytosis in
macrophageswas associatedwith actin cytoskeletal disruption. These
phenotypes may be mediated by oxidative stress, because (1) hy-
drogen peroxide causes actin oxidation resulting in cytoskeletal dis-
ruption [34,35], (2) acute suppression of efferocytosis by CS can be
completely abrogated by the presence of superoxide dismutase, an
anti-oxidant enzyme [9].
As discussed above, the ﬁndings reported here demonstrate that
RvE1 has properties that permit it to downregulate CS-induced oxida-
tive stress. Furthermore, a recent study in our laboratory has shown
that RvE1 can increase the in vivo clearance of E. coli [21]. Therefore,
we speculated that RvE1 could ameliorate the impaired phagocytosis
in CSE-treated RAW264.7 cells. As we expected, RvE1 at a concen-
tration of 10 nM concentration restored the phagocytic function of
macrophages (Fig. 2(B) and (C)), and showedprotective effects against
the disruption of cytoskeletal structure caused by CSE (Fig. 3).
It has been shown that a long term-exposure to hydrogenperoxide
induces the dephospholylation and proteolysis of Akt [36], a serine/
threonine kinase that mediates cell survival, growth, proliferation,
and inﬂammation. In addition, CSE can also induce the proteasomal
degradation of Akt in lung ﬁbroblasts, which leads to cell death [31].
In the present study, we demonstrated that treatment with RvE1 was
able to attenuate cell viability and death, and suppress Akt degrada-
tion in macrophages during long term-CSE exposure (Fig. 4). These
results imply that the regulation of Akt is an another drug target of
interest in terms of the treatment of COPD [37].
In conclusion, our study has demonstrated that, at low concen-
trations, RvE1 can suppress ROS production, ameliorate phagocytic
function, and reduced cell death, in macrophages that have been ex-
posed to CSE. The combined effects of RvE1 on oxidative stress, host
defense, and the enhanced resolution of inﬂammation have new po-
tential therapeutic applications in COPD under stable conditions as
well as during periods of exacerbation. Further studies should be
conducted to investigate the in vivo effects of RvE1 on COPD.
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